Su1787 Long-Term Survival Comparing Carcinoma of the Gastroesophageal Junction With Gastric Cancer - Results of the German Gastric Cancer Study 2

Abstract

Introduction: Data obtained in multicenter studies on quality assurance can reflect the current situation in the treatment of gastric cancer. Adenocarcinoma of the gastroesophageal junction (AGJ) appears to be a separate tumor entity. Methods: Perioperative data on the diagnostic and therapeutic management in gastric cancer patients were collected by means of a prospective multicenter observational study QCGC 2 from 01/01/2007 to 12/31/2009. Early postoperative treatment results and long-term oncological outcome in patients with AGJ with those of the stomach were compared. Results: 2,897 patients with gastric cancer out of 141 hospitals of each profile were enrolled in the study; out of them, 2,788 (96.2 %) underwent surgical intervention. With regard to tumor site, 544 cases with AGJ were operated within 108/141 hospitals (76.6 %) only. Patients with AGJ showed a significantly shorter median survival (25 months) depending on the tumor stage compared with subjects suffering from gastric cancer (38 months). Overall 5-year survival rate of AGJ patients ( 33.1 %) was significantly worse compared with that of individuals with gastric cancer (41.4 %) also depending on single tumor stages according to UICC classification (p<0.001): stage II (46.3 % versus 50 %), III (0 % vs. 22 %) and IV (7.4 % vs. 12 %). Conclusion: The treatment results of gastric cancer patients in hospitals of each profile cannot be satisfying despite a multimodal approach. Prognosis of the carcinoma of the gastroesophageal junction is significantly worse compared with other gastric tumor sites. A centralization of surgical management of these patients seems to be reasonable.